UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study

Lancet neurology, 2014-07, Vol.13 (7), p.657-665

2014

Volltextzugriff (PDF)

Incorporating the Memory Effect of Turbulence Structures Into Suspended Sediment Transport Modeling

Water resources research, 2021-03, Vol.57 (3), p.n/a

2021

Volltextzugriff (PDF)

A stochastic framework for modeling random-sized batch arrivals of sediment particles into open channel flows

Stochastic environmental research and risk assessment, 2018-07, Vol.32 (7), p.1939-1954

2018

Volltextzugriff (PDF)

Stochastic sediment transport: anomalous diffusions and random movement

Stochastic environmental research and risk assessment, 2020-02, Vol.34 (2), p.397-413

2020

Volltextzugriff (PDF)

Incidence, characterization, and clinical impact analysis of peginterferon beta1a immunogenicity in patients with multiple sclerosis in the ADVANCE trial

Therapeutic advances in neurological disorders, 2016-07, Vol.9 (4), p.239-249

2016

Volltextzugriff (PDF)

Long-term outcomes of peginterferon beta-1a in multiple sclerosis: results from the ADVANCE extension study, ATTAIN

Therapeutic advances in neurological disorders, 2018-01, Vol.11, p.1756286418791143-1756286418791143

2018

Volltextzugriff (PDF)

Unilateral subdural motor cortex stimulation improves essential tremor but not Parkinson's disease

Brain (London, England : 1878), 2011-07, Vol.134 (7), p.2096-2105

2011

Volltextzugriff (PDF)

Peginterferon beta-1a reduces disability worsening in relapsing–remitting multiple sclerosis: 2-year results from ADVANCE

Therapeutic advances in neurological disorders, 2017-01, Vol.10 (1), p.41-50

2017

Volltextzugriff (PDF)

Improvement in relapse recovery with peginterferon beta-1a in patients with multiple sclerosis

Multiple sclerosis journal - experimental, translational and clinical, 2016-01, Vol.2, p.2055217316676644-2055217316676644

2016

Volltextzugriff (PDF)

Randomized phase I clinical trial of anti–α‐synuclein antibody BIIB054

Movement disorders, 2019-08, Vol.34 (8), p.1154-1163

2019

Volltextzugriff (PDF)

Incorporating a trend analysis of large flow perturbations into stochastic modeling of particle transport in open channel flow

Journal of hydrology (Amsterdam), 2016-10, Vol.541, p.689-702

2016

Volltextzugriff (PDF)

J04 A prospective observational study of the frequency of single nucleotide polymorphisms (SNP) in patients with huntington’s disease (hd)

Journal of neurology, neurosurgery and psychiatry, 2018-09, Vol.89 (Suppl 1), p.A99

2018

Volltextzugriff (PDF)

Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE

Multiple sclerosis, 2015-07, Vol.21 (8), p.1025-1035

2015

Volltextzugriff (PDF)

Frequency of Single Nucleotide Polymorphisms (SNPs) rs362307 or rs362331 in Patients with Huntington’s Disease (HD): Results from a Prospective Observational Research Study (P4.037)

Neurology, 2018-04, Vol.90 (15_supplement)

2018

Volltextzugriff (PDF)

Pharmacokinetics and pharmacodynamics of peginterferon beta‐1a in patients with relapsing‐remitting multiple sclerosis in the randomized ADVANCE study

British journal of clinical pharmacology, 2015-03, Vol.79 (3), p.514-522

2015

Volltextzugriff (PDF)

ARKD‐104, A Potential Treatment of Frontotemporal Dementia and Other Neurodegenerative Disorders

Alzheimer's & dementia, 2023-12, Vol.19 (S21), p.n/a

2023

Volltextzugriff (PDF)

The Neurofilament Surveillance Project (NSP): A biomarker study to sample blood quarterly in familial frontotemporal lobar degeneration

Alzheimer's & dementia, 2022-12, Vol.18 (S5), p.n/a

2022

Volltextzugriff (PDF)

Subgroup and sensitivity analyses of annualized relapse rate over 2 years in the ADVANCE trial of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis

Journal of neurology, 2016-09, Vol.263 (9), p.1778-1787

2016

Volltextzugriff (PDF)

Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial

BMC neurology, 2017-02, Vol.17 (1), p.29-29, Article 29

2017

Volltextzugriff (PDF)

In Relapsing Multiple Sclerosis, Peginterferon Beta-1a Reduces MRI Lesions Following Relapses (P7.256)

Neurology, 2015-04, Vol.84 (14_supplement)

2015

Volltextzugriff (PDF)

The Efficacy of Peginterferon Beta-1a in Early and Later-Stage Patients With Multiple Sclerosis: A 1-Year Subgroup Analysis Based on Disease Duration from the ADVANCE Study (P7.267)

Neurology, 2015-04, Vol.84 (14_supplement)

2015

Volltextzugriff (PDF)

Long-Term Safety and Tolerability of Peginterferon Beta-1a: Interim Analysis From ATTAIN, a Phase 3 Extension Study (S4.002)

Neurology, 2015-04, Vol.84 (14_supplement)

2015

Volltextzugriff (PDF)

Peginterferon Beta-1a is Effective as Early as Twelve Weeks Following Treatment Initiation in Patients With Relapsing Multiple Sclerosis (S4.001)

Neurology, 2015-04, Vol.84 (14_supplement)

2015

Volltextzugriff (PDF)

Pharmacokinetics, pharmacodynamics, and safety of peginterferon beta-1a in subjects with normal or impaired renal function

Journal of clinical pharmacology, 2015-02, Vol.55 (2), p.179-188

2015

Volltextzugriff (PDF)

1 – 25 von 72

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(65)
Mit Volltextzugriff
(45)

Publikationsform

Sprache

Englisch
(72)

Erscheinungsjahr

n.n

Thema

Science & Technology
(36)
Life Sciences & Biomedicine
(29)
Humans
(18)
Clinical Neurology
(15)
Neurosciences & Neurology
(15)
Female
(14)
Male
(14)
Middle Aged
(14)
Multiple Sclerosis
(12)
Adult
(11)
Interferon
(9)
Treatment Outcome
(9)
Aged
(7)
Double-Blind Method
(7)
Multiple Sclerosis, Relapsing-Remitting - Drug Therapy
(7)
Interferon-Beta - Therapeutic Use
(6)
Peginterferon Beta-1a
(6)
Pegylation
(6)
Polyethylene Glycols - Therapeutic Use
(6)
Clinical Trial
(5)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study

Incorporating the Memory Effect of Turbulence Structures Into Suspended Sediment Transport Modeling

A stochastic framework for modeling random-sized batch arrivals of sediment particles into open channel flows

Stochastic sediment transport: anomalous diffusions and random movement

Incidence, characterization, and clinical impact analysis of peginterferon beta1a immunogenicity in patients with multiple sclerosis in the ADVANCE trial

Long-term outcomes of peginterferon beta-1a in multiple sclerosis: results from the ADVANCE extension study, ATTAIN

Unilateral subdural motor cortex stimulation improves essential tremor but not Parkinson's disease

Peginterferon beta-1a reduces disability worsening in relapsing–remitting multiple sclerosis: 2-year results from ADVANCE

Subthalamic deep brain stimulation with a constant-current device in Parkinson's disease: an open-label randomised controlled trial

Improvement in relapse recovery with peginterferon beta-1a in patients with multiple sclerosis

Randomized phase I clinical trial of anti–α‐synuclein antibody BIIB054

Incorporating a trend analysis of large flow perturbations into stochastic modeling of particle transport in open channel flow

J04 A prospective observational study of the frequency of single nucleotide polymorphisms (SNP) in patients with huntington’s disease (hd)

Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE

Frequency of Single Nucleotide Polymorphisms (SNPs) rs362307 or rs362331 in Patients with Huntington’s Disease (HD): Results from a Prospective Observational Research Study (P4.037)

Pharmacokinetics and pharmacodynamics of peginterferon beta‐1a in patients with relapsing‐remitting multiple sclerosis in the randomized ADVANCE study

ARKD‐104, A Potential Treatment of Frontotemporal Dementia and Other Neurodegenerative Disorders

The Neurofilament Surveillance Project (NSP): A biomarker study to sample blood quarterly in familial frontotemporal lobar degeneration

Subgroup and sensitivity analyses of annualized relapse rate over 2 years in the ADVANCE trial of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis

Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial

In Relapsing Multiple Sclerosis, Peginterferon Beta-1a Reduces MRI Lesions Following Relapses (P7.256)

The Efficacy of Peginterferon Beta-1a in Early and Later-Stage Patients With Multiple Sclerosis: A 1-Year Subgroup Analysis Based on Disease Duration from the ADVANCE Study (P7.267)

Long-Term Safety and Tolerability of Peginterferon Beta-1a: Interim Analysis From ATTAIN, a Phase 3 Extension Study (S4.002)

Peginterferon Beta-1a is Effective as Early as Twelve Weeks Following Treatment Initiation in Patients With Relapsing Multiple Sclerosis (S4.001)

Pharmacokinetics, pharmacodynamics, and safety of peginterferon beta-1a in subjects with normal or impaired renal function

Suchergebnisse filtern